Advancing the care of patients suffering from chronic lower back pain

Jeff Thramann is the Executive Chairman and Director at Aclarion. He oversees strategic initiatives, capitalization, and governance at the company. Dr. Thramann is a serial entrepreneur who has founded consumer and medtech companies such as Auddia Inc. (NASDAQ: AUUD,) Lanx, LLC (sold to Biomet Inc. November 2013,) ProNerve, LLC. (sold to Waud Capital Partners 2012,) and U.S. Radiosurgery (sold to Alliance Healthcare Services (NASDAQ: AIQ) April 2011.)

Dr. Thramann is also an accomplished neurosurgeon who founded and was a senior partner of Boulder Neurosurgical Associates, a neurosurgical practice serving Boulder County, Colorado. Dr. Thramann is the named inventor on over 100 U.S. and international issued and pending patents. He completed his neurosurgical residency and complex spinal reconstruction fellowship at the Barrow Neurological Institute in Phoenix, AZ and is a graduate of Cornell University Medical College in New York City. He also earned his Bachelor of Science degree in electrical engineering management at the U. S. Military Academy in West Point, NY.

Mr. Ness became the Chief Executive Officer of Aclarion in September 2021. Mr. Ness has over 25 years of medical device and healthcare technology experience and has held various executive and senior leadership positions, including recently as CCO of Cleerly, Inc. At Cleerly, Mr. Ness built key industry partnerships with Canon Inc. to drive adoption of their AI-enabled cardiology solution. Previously, Mr. Ness was also the Chief Operating Officer of Mighty Oak Medical (“Mighty Oak”) whose principal products progressed from pre-FDA clearance through an international full market launch of their platform called FIREFLY.

Mr. Ness was also Chief Commercial Officer of HeartFlow, Inc., (“Heartflow”). Mr. Ness led Hearflow from pre-FDA clearance through a global expansion of early adopter sites. He also served as President of ProNerve, LLC, (“ProNerve) where he led a roll up of the highly fragmented Interoperative Nerve Monitoring Industry.

Mr. Ness has also held senior leadership roles at Medtronic, GE Healthcare, and Philips North America.

Mr. Neal has been on the Aclarion Board of Directors since September 2016. He is the founder and a current member of SC Capital 1 LLC, a securitized LLC formed to invest in breakthrough medical technologies and therapies. He is also a partner of Frontier Wealth Enterprises, LLC a financial services firm providing advice-based financial services to high net-worth families. He has held various positions with UBS, including Portfolio Manager and Regional Office Manager in Wichita Kansas. He was on the Hutchinson Regional Medical Center Board of Directors for 9 years and currently sits on the boards of The Cosmosphere, a world-class space museum & STEM education center, and the Hutchinson Community Foundation.

In 2007, Mr. Neal and his wife, Karin, started the John & Michael Neal Foundation for Cancer Research to raise money to help fund research for cancer research and breakthrough medical technologies across the globe. He holds a Bachelor of Sport Science degree from the University of Kansas and a Master of Management Science degree from the John Cook School of Business at Saint Louis University.

Mr. Wesemann has been on the Aclarion Board of Directors since 2016. Mr. Wesemann has been an independent businessman and investor since June 2002. Prior to 2002 his experience included serving in chief executive, sales leadership, and advisory roles at various technology companies. He has been a director of LivePerson (Nasdaq: LPSN), a global technology company that develops conversational commerce and AI software. He is also a director of Stationhead, Inc., a consumer social audio platform; and a director of Mylio, Inc, a photo management company. Mr. Wesemann received a B.A. from Glassboro State College (Rowan University).

Ms. Sequira is currently the Senior Vice President of Clinical, Quality and Regulatory at ViewRay, Inc. (Nasdaq: “VRAY”), a healthcare company that integrates real time MRI imaging of tumors with the delivery of high dose radiation for improved treatment accuracy. She brings 20 years of experience in the medical device space to the Aclarion board. She was the Head of Regulatory with the Image Guided Therapy Devices and Systems divisions of Philips and the Senior Director and Vice President of Clinical and Regulatory with The Spectranetics Corp., (now part of Philips).

From 2003 to 2010 she was Manager, and then Director of Regulatory of AGA Medical Corp (now part of Abbott). Prior to these roles, she worked as a Regulatory Specialist with Vascular Solutions and as a Chemist with GE – Osmonics. She holds a Master’s of Science in Regulatory from Northeastern University and a Bachelor’s of Science in Chemistry from the University of Minnesota.

Steve Deitsch is the CFO of Paradigm 28, a medical device company focused on surgical implants for the foot and ankle. Steve has extensive strategic, operational, and financial executive and senior leadership experience at both publicly traded and privately held companies, including BioScrip, Inc. (now part of Option Care Health, Inc. (NASDAQ: BIOS),) Coalfire, Inc., Zimmer Biomet Spine, Lanx (acquired by Biomet October 2013.) He also held various senior financial leadership roles at Zimmer Holdings, Inc. (now part of Zimmer Biomet, Inc.)

Steve is current on the Board of Directors at Green Sun Medical, a privately held medical device company, and a board member and audit committee chair of Auddia Inc. (NASDAQ: AUUD).

Dr. Scott Breidbart has an extensive background in health care delivery. He is an advisor to Redesign Health and a consultant for Stellar Health. Redesign Health is a mission-driven innovation platform that launches transformative healthcare companies. Stellar Health is a healthcare technology company focused on enabling success across the value-based care continuum by bridging the incentive gap between providers and payors.

Dr. Breidbart has an over 20 year history in managed care, most recently as the Chief Medical Officer of Affinity Health Plans. He has also served as Chief Medical Officer of Solera Health, the Chief Clinical Officer of Emblem Health, the Chief Medical Officer of Empire BlueCross BlueShield, and has held various roles in medical management for HealthNet. Dr. Breidbart practiced pediatric endocrinology for ten years on the faculty of New York Medical College. He is Board Certified in Pediatrics and Pediatric Endocrinology and is licensed to practice medicine in NY. He holds a BA in Mathematics from Yale, an MD from Columbia, and an MBA from Pace University.